Digital tools & #AI may help detect and manage treatment related toxicities during chemoradiotherapy.
A study in ESMO Real World Data and Digital Oncology highlights both the promise and challenges of continuous activity monitoring.
#ESMODailyReporter 🔗 https://ow.ly/Njbk50YGnOn
Rodrigo Dienstmann

ESMO has supported fellows and research worldwide for years.

The Leadership and Career Development Award combines leadership training & research opportunities globally.

📅 Apply by 3 May 2026

🔗https://ow.ly/ZgRW50Yyv3k

#ESMOYOC #Oncology #CareerDevelopment

📣 Submit your research to MAP 2026! Abstract submission is now open for this leading precision oncology congress, taking place 10–11 September in London. Deadline: 2 June 2026. #MAP2026 #esmomeetings

🔗 https://ow.ly/I8Te50YvmSo

👉 #ESMOTAT26 resources are now available!

Delegates and ESMO members can now access presentations, abstracts and session materials on #OncologyPRO.

🔗 Explore the materials: https://ow.ly/yNYq50Yvpl1

#ESMOMeetings

#ESMOTAT26: Fostering academic #ClinicalResearch is one of the ESMO’s priorities, and #ArtificialIntelligence may be a major driver.
Read the Editorial by @fandremd.bsky.social in the #ESMODailyReporter ➡️ https://ow.ly/JYkz50YuzTr

#ESMOTAT26: In his interview in the #ESMODailyReporter, Timothy A. Yap, TAT Honorary Awardee, shares insights on innovative approaches to exploit synthetic lethality to ‘drug the undruggable’
📌https://ow.ly/FkSE50YuA7Q

#DrugDevelopment

👉 Stay at the cutting edge of rare cancers

All authorised congress sessions from ESMO Sarcoma and Rare Cancers 2026 are now on #OncologyPRO for registered delegates & ESMO members

Explore the science anytime, anywhere
🔗 https://ow.ly/nJlY50YuMvG

#ESMORareCancers26 #esmomeetings

Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawelsobczuk.bsky.social
explains more in his Opinion piece in the #ESMODailyReporter ➡️https://ow.ly/Gr0t50YtqJj

#ESMORareCancers26

Honoured for having the opportunity to present some of our work Dr Nagaraju Prof Aziz on #appendixcancer at #ESMORareCancers26
Glad to see you back Dr Strach and Prof Deraco
Thank you Drs Shiu and Wyrwicz for moderating the session!
@myesmo.bsky.social

#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced with safety and fertility considerations. Check out the #ESMODailyReporter: https://ow.ly/8jpy50YsKVz

#ESMORareCancers26: Preliminary data with the DR5 agonist, ozekibart, added to chemotherapy indicate robust activity and a manageable safety profile in relapsed/refractory #EwingSarcoma. Learn more ➡️https://ow.ly/fR7Z50Ytqq5

#ESMODailyReporter

🏆 Congratulations to the #ESMOMeritAward recipients at #ESMORareCancers26

These young researchers were recognised for the scientific merit of their abstracts.

🔗https://ow.ly/CPuX50YsfWE
#RareCancers #Oncology #Sarcoma

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9

🎉 50 years. 50,000 professionals. Advancing #oncology.
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer.

#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt

'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'

Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇

#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY

#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM

#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL

The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI

#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo

📣 Registration for #ESMOTATAsia26 is open! Join global experts in #precisiononcology and discover the latest breakthroughs in cancer #drugdevelopment

🔗 https://ow.ly/oQRg50XBOZZ

⏰ Early Registration applies until 8 April 2026.

In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee

#ESMOAsia25

🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings

👉 Together, we shape the future of oncology: buff.ly/qHVAi4F

#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ

#ESMODailyReporter

ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64

#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL

#ESMODailyReporter

Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu

#ESMODailyReporter

People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...

#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE